8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Using in-vivo microdialysis, we examined the effect of the serotonin 5-HT1A agonist R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin on striatal extracellular excitatory amino acids in an animal model of Parkinson's disease. Extracellular glutamate and aspartate in the dopamine-denervated striatum of unilateral 6-hydroxydopamine-lesioned rats were significantly decreased by acute subcutaneous injection of R-(+)-8-hydroxy-2-(di-n-propylamino) tetralin (0.3 mg/kg). Although not quantified in the present study, a concomitant increase in locomotor activity was anecdotally observed following R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin. These results suggest that systemic administration of a 5-HT1A agonist can reduce glutamate neurotransmission in the dopamine-denervated striatum. The results are discussed with respect to the treatment of Parkinson's disease.
Mignon
Laurence J
LJ
Department of Neurology, David Geffen School of Medicine at UCLA, B114 Reed Neurology Research Center, Los Angeles, CA 90095, USA.
Wolf
William A
WA
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology*; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003714:Denervation; D004195:Disease Models, Animal; D018698:Glutamic Acid / Q000378:metabolism*; D007279:Injections, Subcutaneous; D008297:Male; D017551:Microdialysis; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000494:pharmacology*; D013565:Sympatholytics
D017366:Serotonin Receptor Agonists; D013565:Sympatholytics; D001224:Aspartic Acid; D012701:Serotonin; D018698:Glutamic Acid; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D016627:Oxidopamine